Composition for treating diseases caused by cytokine storm
A benzamide compound with Hsp90 inhibitory activity addresses the lack of effective cytokine storm treatments by inhibiting T cell markers and cytokine secretion, effectively managing severe inflammatory and immune diseases.
Patent Information
- Application Number
- KR1020240070128
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-05-29
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2044-05-29
AI Technical Summary
Current treatments lack effective Hsp90 inhibitors to mitigate cytokine storms, which can lead to severe inflammatory and immune diseases such as acute lung injury, delayed-type hypersensitivity, acute pneumonia, allergic asthma, and diabetes mellitus, with existing technologies failing to regulate extreme immune responses effectively.
A pharmaceutical and health functional food composition containing a benzamide compound with Hsp90 inhibitory activity, inhibiting the expression of T cell-associated markers on dendritic cells and macrophages, thereby reducing the secretion of pro-inflammatory cytokines.
The compound effectively suppresses cytokine storms by reducing the expression of CD86, CD80, MHC I, and MHC II markers and inhibiting the secretion of IL-6, TNF-α, IL-12 (p70), IL-1β, and IFN-γ, thus preventing or treating inflammatory and immune diseases.
Smart Images

Figure 112024058346073-PAT00012_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a composition for treating diseases caused by a cytokine storm, and more specifically, to a composition for treating inflammatory or immune diseases caused by a cytokine storm comprising a compound having Hsp90 inhibitory activity. Background Technology
[0002] Inflammatory responses occur when the innate immune system detects antigens from outside the body and are essential for protecting the body from pathogens. However, uncontrolled immune responses can lead to cytokine storms and autoimmune diseases. Excess cytokines remaining from initial inflammation stimulate immune cells again, triggering a secondary excessive cytokine response; the excessive inflammatory response and immune cell abnormalities resulting from this cytokine storm can cause serious problems in the body and lead to death. The COVID-19 pandemic starkly highlighted the severe risks associated with excessive inflammatory responses caused by cytokine storms. Therefore, there is a growing need for the development of drugs capable of regulating extreme immune responses with minimal side effects.
[0003] Dendritic cells (DCs) are sentinel immune cells and antigen-presenting cells (APCs) found in peripheral tissues. Upon encountering an antigen, DCs undergo 'maturation' that promotes T cell activation, initiating an inflammatory response to the entry of pathogens. For T cell activation, DCs must satisfy the following various conditions: (a) capture and processing of the antigen, (b) expression of antigen peptides via MHC molecules, (c) expression of T cell co-stimulatory molecules CD80 and CD86, and (d) physical contact with antigen-specific T cells.
[0004] To activate CD4 helper T cells, a secondary signal mediated by CD80 and CD86 molecules is required, along with a primary signal from the DC's MHC II-antigen complex. After priming T cell stimulation, they differentiate into type 1 helper T cells (Th1) or type 2 helper T cells (Th2). In particular, Th1 cells that produce IFN-γ induce effector T cells and cytotoxic T (Tc) cells of cellular immunity similar to Th1, thereby exacerbating the inflammatory response. Additionally, IFN-γ induces the activation of macrophages and causes them to secrete inflammatory cytokines such as IL-6, TNF-α, and IL-1β. These inflammatory cytokines stimulate and recruit granulocytes to produce additional inflammatory cytokines.
[0005] Ultimately, this positive feedback loop can lead to a cytokine storm and septic shock, and can cause Acute Respiratory Distress Syndrome (ARDS), particularly in the lungs. Delayed-type hypersensitivity (DTH) is one of the allergic immune responses associated with cellular immune responses induced by Th1 cells and Tc cells, starting with antigen-presenting cells (APCs) as the antigen. Antigen-specific effector T cells and activated macrophages gather at the reaction site, and consequently, DTH is characterized by unregulated inflammation.
[0006] Heat shock protein 90 (Hsp90) acts as a chaperone that supports the folding and maturation of intracellular proteins. While its potential for cancer prevention and anti-inflammatory effects is being studied, no promising Hsp90 inhibitors for mitigating cytokine storms have been reported to date. Prior art literature
[0007] Republic of Korea Published Patent No. 10-2009-0080948 (Published July 27, 2009) The problem to be solved
[0008] The objective of the present invention is to provide a composition for treating inflammatory or immune diseases having excellent Hsp90 inhibitory activity.
[0009] Another objective of the present invention is to provide a composition for suppressing cytokine storms.
[0010] Another objective of the present invention is to provide a method for suppressing a cytokine storm. means of solving the problem
[0011] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory or immune diseases, comprising as an active ingredient a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:
[0012] <Chemical Formula 1>
[0013]
[0014] The present invention provides a health functional food composition for the prevention or improvement of inflammatory or immune diseases, comprising a compound represented by the above chemical formula 1 or a food-grade acceptable salt thereof as an active ingredient.
[0015] The present invention provides a composition for suppressing a cytokine storm, comprising a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
[0016] In addition, the present invention provides a method for suppressing a cytokine storm, comprising the step of treating a target with a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof. Effects of the invention
[0017] The present invention relates to novel uses of Hsp90 inhibitory compounds. The compound according to the present invention or a pharmaceutically / food-acceptable salt thereof has excellent Hsp90 inhibitory activity, inhibits the expression of T cell-associated markers on the surface of dendritic cells or macrophages, and can inhibit the secretion of various pro-inflammatory cytokines.
[0018] The compound or salt thereof according to the present invention can prevent, treat, or improve inflammatory or immune diseases associated with the same by regulating cytokine storms through the above-mentioned effects. Brief explanation of the drawing
[0019] Figure 1 shows the results of compound screening for the inhibition of CD86 expression in dendritic cells (DC), (a) shows the results of flow cytometry analysis after treating splenocytes with 137 compounds (1 μM) for 24 hours and staining them with anti-CD11c (FITC) and anti-CD86 (PE) antibodies, with the data expressed as mean fluorescence intensity (MFI). (b) shows the results of measuring CD86 expression levels by flow cytometry after culturing splenocytes with five selected compounds (Bd03, Be01, Bc03, Bf01, Bd04; 1 μM each) and LPS (1 μg / mL) for 24 hours, (c) shows the changes in expression of other surface molecules such as CD80, MHC I, and MHC II following treatment with the five compounds under LPS treatment conditions, and (d) shows the cytotoxicity of compounds Be01 and Bf01 evaluated using CCK-8 analysis. Figure 2 analyzes the inhibitory effect of the Be01 compound on DC and antigen-specific T cell responses. (a) shows the results of flow cytometry analysis performed after treating bone marrow-derived dendritic cells (BMDCs) with LPS followed by Be01, staining with anti-CD11c (FITC) and anti-CD86 (PE) antibodies, and the data were described by the mean fluorescence intensity ratio. (b) shows the secretion of IL-6, TNF-α, IL-12 (p70), and IL-1β by Be01 (1 μM) in LPS-stimulated BMDCs measured by ELISA. (c) shows the process of co-culturing OVA-specific Th1 cells with C57BL / 6-derived BMDCs treated with OVA and Be01 for 48 hours. (d) shows the proliferation of OVA-specific Th1 cells evaluated using the BrdU labeling kit (left) and the IFN-γ level measured by ELISA after collecting the culture supernatant after 24 hours (right). ND (Not detected) indicates cytokine secretion of less than 1.1 pg / mL in this experiment. Figure 3 analyzes the anti-inflammatory effect on peritoneal macrophages, (a) is a schematic diagram of the experiment on peritoneal macrophages of C57BL6 mice, and (b) is peritoneal macrophages (1×10⁻⁶ 5 The cytotoxicity of cells was measured by CCK-8 analysis 24 hours after treatment with Be01 (0.1, 0.3, and 1 μM). (c) shows the analysis of NO production after treating LPS (1 μg / mL)-stimulated peritoneal macrophages with Be01, with nitric oxide concentration measured using the Griess reaction as an indicator of NO production. (d) shows the results of flow cytometry analysis after staining cells with anti-CD11c (FITC) and anti-CD86 (PE) antibodies, and (e) shows the secretion of IL-6, TNF-α, and IL-1β by Be01 from LPS-stimulated peritoneal macrophages measured by ELISA. Figure 4 analyzes the anti-inflammatory effects in mouse OVA-specific delayed-type hypersensitivity (DTH) and acute lung injury (ALI) models. (a) is a schematic diagram of the BALB / c mouse OVA-specific DTH model (n=5), in which BALB / c mice were sensitized with 100 μL of OVA (100 μg / mL) and a CFA emulsion, and the experimental group was treated daily with 100 μL of BeO1 (100 μM) for 6 days leading up to the OVA test. (b) is a representative image (scale bar: 50 μm) of the mouse left ear auricular tissue and H&E staining. (c) shows the left ear thickness measured 24 hours after the OVA test. (d) shows the results of measuring the secretion of IL-6, TNF-α, and IL-1 by BeO1 (1 μM) in the supernatant of OVA-stimulated splenocytes using ELISA. (e) is a schematic diagram of a mouse ALI model (n=3) using C57B / 6 mice. (f) is a representative image of lung cryopreservation and H&E staining of C57B / 6 mice (scale bar: 650 μm), and (g) is an image of infiltrated neutrophils (CD45 + , CD11b + , and Gr-1 + The number of ) was counted by flow cytometry, and (h) is the result of measuring the secretion levels of IL-6, TNF-α, IL-12 (p70), and IL-1β by Be01 (1 μM) using ELISA. Specific details for implementing the invention
[0020] The present invention will be described in detail below.
[0022] The inventors completed the present invention by screening Hsp90 inhibitory compounds that inhibit the function of dendritic cells and macrophages using a compound library of Hsp inhibitors, and by confirming that said compounds inhibit cytokine production and the expression of surface molecules, and that these effects are also exhibited in animal models of acute lung injury (ALI) and delayed-type hypersensitivity (DTH).
[0024] The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory or immune diseases, comprising as an active ingredient a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:
[0025] <Chemical Formula 1>
[0026]
[0028] The above compound is a benzamide compound having heat shock protein 90 (Hsp90) inhibitory activity, and the above compound can be used in the form of a pharmaceutically or food-acceptable salt, and the salt is a salt of the compound that does not cause significant irritation to the organism to which it is administered, and does not lose the biological activity and properties of the above compound.
[0029] In this specification, "pharmaceutical or food-acceptable" means a salt having a safety and efficacy profile suitable for administration to humans, having no toxicity to cells or humans exposed to the composition.
[0030] The above salt may be used in the form of either a basic salt or an acidic salt that is pharmaceutically or food-grade acceptable. For example, the basic salt may include either an organic basic salt or an inorganic basic salt, and may be selected from the group consisting of sodium salt, potassium salt, calcium salt, lithium salt, magnesium salt, cesium salt, aluminum salt, ammonium salt, triethylaminium salt, and pyridinium salt, but is not limited thereto.
[0031] Acid salts formed by free acids are useful. Inorganic and organic acids can be used as free acids. Inorganic acids may include hydrochloric acid, bromic acid, sulfuric acid, sulfite, phosphoric acid, etc., and organic acids may include citric acid, acetic acid, maleic acid, fumaric acid, glutonic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, oxalic acid, malonic acid, glutaric acid, acetic acid, glyconic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, emvonic acid, glutamic acid, citric acid, aspartic acid, stearic acid, etc., but are not limited thereto and may include all salts formed using various inorganic and organic acids commonly used in the industry.
[0032] The above compound may include not only the above salt but also all salts, hydrates, solvates, derivatives, etc. that can be prepared by conventional methods, and the addition salt may be prepared by conventional methods. For example, the above compound may be prepared by dissolving it in a water-miscible organic solvent, such as acetone, methanol, ethanol, or acetonitrile, adding an excess amount of organic base or an aqueous solution of an inorganic base, and then precipitating or crystallizing it. Alternatively, the addition salt may be obtained by drying the mixture after evaporating the solvent or the excess base, or by suction filtration of the precipitated salt.
[0034] The above compound or its salt can inhibit the expression of T cell-associated markers selected from the group consisting of CD86, CD80, MHC I, and MHC II on the surface of dendritic cells or macrophages, and can inhibit the secretion of pro-inflammatory cytokines selected from the group consisting of IL-6, TNF-α, IL-12 (p70), IL-1β, and IFN-γ.
[0035] Inhibition of the expression of T cell-related markers in dendritic cells or macrophages by the above compound or its salt can reduce the function as antigen-presenting cells and thereby reduce the secondary inflammatory response by T cells, and is also effective in controlling the cytokine storm in the early stages by reducing the release of pro-inflammatory cytokines.
[0037] Accordingly, the above compound or its salt can be utilized as a pharmaceutical composition for the prevention or treatment of inflammatory or immune diseases caused by cytokine storms.
[0038] The inflammatory or immune disease caused by the above cytokine storm may specifically be one or more selected from the group consisting of acute lung injury (ALI), delayed-type hypersensitivity (DTH), acute pneumonia, allergic asthma, rheumatoid arthritis, and diabetes mellitus, but is not limited thereto.
[0040] In this specification, the term "pharmaceutical composition" refers to a composition administered for the purpose of preventing or treating a specific disease, and for the purposes of the present invention, means administered to prevent or treat an inflammatory disease or immune disease caused by a cytokine storm, or at least one of the symptoms thereof.
[0041] The pharmaceutical composition according to the present invention may be prepared according to conventional methods in the pharmaceutical field. The pharmaceutical composition may be combined with a suitable pharmaceutically acceptable carrier according to the formulation, and may be prepared by further including excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, etc., as needed. The suitable carrier, etc., may be selected differently depending on the dosage form and formulation, as it does not impair the activity and properties of the compound according to the present invention or its pharmaceutically acceptable salt.
[0042] The pharmaceutical composition according to the present invention can be applied in any dosage form, and more specifically, can be formulated and used in oral dosage forms, topical preparations, suppositories, and parenteral dosage forms such as sterile injectable solutions according to conventional methods, but is not limited thereto.
[0043] Among the above oral formulations, solid formulations may be in the form of tablets, pills, powders, granules, capsules, etc., and may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, gelatin, etc., and may also include lubricants such as magnesium stearate and talc in addition to simple excipients. Furthermore, in the case of capsule formulations, in addition to the substances mentioned above, liquid carriers such as fatty oils may be further included. Among the above oral formulations, liquid formulations may include suspensions, liquid formulations, emulsions, syrups, etc., and may include various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
[0044] The parenteral formulations described above may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, witepsol, macrogol, Tween 61, cacao oil, laurin oil, glycerogelatin, etc., may be used. However, they are not limited thereto, and any suitable formulation known in the art may be used.
[0046] In the pharmaceutical composition according to the present invention, the pharmaceutical composition may be administered in a pharmaceutically effective amount.
[0047] In this specification, "pharmaceuticalally effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause adverse effects.
[0048] The effective dose level of the above pharmaceutical composition may be determined differently depending on factors including the purpose of use, the patient's age, gender, weight and health status, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. For example, although not constant, it may generally be administered at a dose of 0.001 to 1000 mg / kg, preferably 0.01 to 100 mg / kg, once or several times daily. The above dosage does not limit the scope of the present invention in any way.
[0050] The pharmaceutical composition according to the present invention may be administered to any animal capable of developing an inflammatory or immune disease caused by a cytokine storm, and said animal may include, for example, humans and primates, as well as livestock such as cattle, pigs, horses, and dogs.
[0051] The pharmaceutical composition according to the present invention may be administered via a suitable route of administration depending on the formulation form, and may be administered via various routes, oral or parenteral, as long as it can reach the target tissue. The method of administration may be administered by conventional methods, such as oral, rectal or intravenous, intramuscular, topical application, respiratory inhalation, intrathecal or intracerebral (intracere-broventricular) injection, without needing to be particularly limited.
[0052] The pharmaceutical composition according to the present invention may be used alone for the prevention or treatment of inflammatory or immune diseases caused by cytokine storm, or may be used in combination with surgery or other drug treatments.
[0054] The present invention provides a health functional food composition for the prevention or improvement of inflammatory or immune diseases, comprising as an active ingredient a compound represented by the following chemical formula 1 or a food-grade acceptable salt thereof:
[0055] <Chemical Formula 1>
[0056]
[0058] The above compound or its salt can suppress the expression of T cell-related markers selected from the group consisting of CD86, CD80, MHC I, and MHC II on the surface of dendritic cells or macrophages, and can suppress the secretion of pro-inflammatory cytokines selected from the group consisting of IL-6, TNF-α, IL-12 (p70), IL-1β, and IFN-γ, thereby regulating cytokine storms; thus, the above compound or its salt can be utilized as a health functional food composition for the prevention or improvement of inflammatory or immune diseases caused by cytokine storms.
[0059] Corresponding features can be substituted with those described above.
[0061] In this specification, "health functional food" refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body pursuant to Article 6727 of the Act on Health Functional Foods, and means a food with high medical or medical effects that is processed to efficiently exhibit biological regulatory functions such as prevention of inflammatory or immune diseases caused by cytokine storms or symptoms thereof, biological defense, immunity, and recovery, in addition to nutritional supply, for the purposes of the present invention.
[0063] In the health functional food composition according to the present invention, the health functional food may be manufactured in the form of powder, granules, tablets, capsules, syrup, or beverage for the purpose of preventing or improving inflammatory or immune diseases caused by cytokine storm. There are no restrictions on the form in which the health functional food may take, and it may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods.
[0064] In the health functional food composition according to the present invention, the health functional food may include all foods in the conventional sense. For example, beverages and various drinks, fruits and processed foods thereof (canned fruit, jam, etc.), fish, meat and processed foods thereof (ham, bacon, etc.), breads and noodles, cookies and snacks, dairy products (butter, cheese, etc.), etc., may be included, and may include all functional foods in the conventional sense. In addition, foods used as animal feed may also be included.
[0066] The health functional food composition according to the present invention may be manufactured by further including food-grade acceptable food additives (food additives) commonly used in the industry and appropriate other auxiliary components. Unless otherwise stipulated, suitability as a food additive may be determined by the specifications and standards regarding the relevant item in accordance with the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety. Examples of items listed in the above 'Food Additives Codex' include chemically synthesized products such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamon acid; natural additives such as persimmon dye, licorice extract, crystalline cellulose, sorghum dye, and guar gum; and mixed preparations such as L-sodium glutamate preparations, alkaline noodle additives, preservative preparations, and tar dye preparations.
[0067] The above other auxiliary ingredients may additionally contain, for example, flavoring agents, natural carbohydrates, sweeteners, vitamins, electrolytes, coloring agents, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents, etc. In particular, the above natural carbohydrates may include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol, and as sweeteners, natural sweeteners such as taumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used.
[0069] The effective dose of the compound or its salt contained in the health functional food according to the present invention can be appropriately adjusted according to the purpose of use, such as the prevention or improvement of inflammatory or immune diseases caused by cytokine storm.
[0070] The above-mentioned health functional food composition has the advantage of being made from food ingredients and not having the side effects that may occur with long-term use of general medicines, and is highly portable, so it can be consumed as an adjuvant for the prevention or improvement of inflammatory or immune diseases caused by cytokine storms.
[0072] The present invention provides a composition for suppressing a cytokine storm, comprising as an active ingredient a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:
[0073] <Chemical Formula 1>
[0074]
[0076] The above compound or its salt can inhibit the expression of T cell-related markers selected from the group consisting of CD86, CD80, MHC I, and MHC II on the surface of dendritic cells or macrophages, and can inhibit the secretion of pro-inflammatory cytokines selected from the group consisting of IL-6, TNF-α, IL-12 (p70), IL-1β, and IFN-γ, thereby allowing for the regulation of cytokine storms.
[0078] Alternatively, the present invention provides a reagent composition for suppressing cytokine storms, comprising as an active ingredient a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:
[0079] <Chemical Formula 1>
[0080]
[0082] In addition, the present invention provides a method for suppressing a cytokine storm, comprising the step of treating a target with a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:
[0083] <Chemical Formula 1>
[0084]
[0086] The above subject may be a mammal, excluding a human, that has developed an inflammatory or immune disease due to a cytokine storm, but is not limited thereto.
[0088] Hereinafter, the present invention will be described in detail with reference to examples to aid in understanding. However, the following examples are merely illustrative of the content of the present invention and the scope of the present invention is not limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those with average knowledge in the art.
[0090] <Experimental Method>
[0091] 1. Materials and Analytical Instruments
[0092] All reagents and solvents were purchased from commercial suppliers and used without further purification. Experiments involving moisture-sensitive materials were performed under an inert atmosphere using argon, and rotary evaporators were used for evaporation and concentration. Analytical thin-layer chromatography (TLC) was performed on pre-coated silica gel F254 TLC plates (Merck, Darmstadt, Germany) and visualized under a UV lamp or iodine stain. Column chromatography was performed using silica gel (Merck Silica Gel 40-63 μm, Darmstadt, Germany) with a hexane and ethyl acetate mobile phase under medium pressure. Medium-pressure liquid chromatography (MPLC) was performed using a Biotage Isolera One instrument equipped with 254 nm and 280 nm UV detectors and silica gel cartridges (Biotage SNAP HP-Sil, Uppsala, Sweden). Nuclear magnetic resonance (NMR) analysis was performed using a JEOL (JNM-ECZ500R, 500 MHz, Peabody, Massachusetts, USA) instrument. Chemical shift was calculated in parts per million using the deuterium lock signal of the sample solvent used as a reference ( δIt was reported in units of ). Combination constant ( J ) was provided in Hertz (Hz). The split pattern abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublet; td, triplet of doublet; m, multiplet. Mass spectrometry was performed using an Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight Liquid Chromatography / Mass Spectrometry (Q-TOF LC / MS) system with an Agilent 1290 Infinity LC (Agilent Technologies, Santa Clara, California, USA).
[0094] 2. Compound Library
[0095] The in-house small molecule library used for screening analysis consists of 137 synthetic products developed in previous studies. (Eur J Med Chem 2018, 143, 390-401, Eur J Med Chem. 2016124:1069-1080, Arch Pharm Res. 2017 Jan;40(1):96-105, Bioorg Med Chem Lett. 2014 Jan 1;24(1):224-7, Arch Pharm Res. 2015 Oct;38(10):1783-8).
[0097] 3. Synthesis of Be01 Compounds
[0098] Compound Be01 was developed in this laboratory as an Hsp90 inhibitor. The synthesis pathway of the target compound Be01 is as shown in Reaction Scheme 1 below:
[0099] <Reaction Equation 1>
[0100]
[0101] (a) MeNH2, NaBH4, MeOH, rt, 2 h, 92%; (b) EDC, HOBt, DIPEA, DMF, rt, 6 h, 65%; (c) LiOH·HO, MeOH, HO, rt, 12 h, 96%; (d) Propyl amine, EDC, HOBt, DIPEA, DMF, rt, 6h, 72%
[0103] The above reaction scheme followed a similar pathway with slight modifications to our previous study (EJMC 2018, 143, 390-401).
[0104] Commercially available methyl 4-formylbenzoate (1) was reduced and aminated with methyl amine (MeNH2) followed by sodium borohydride (NaBH4) to obtain the desired precursor 2 in 92% yield. The obtained compound 2 was treated with 2,4-dihydroxy-5-isopropylbenzoic acid (3) in the presence of EDC, HOBt, and DIPEA in DMF to obtain compound 4 in 65% yield. Alkaline hydrolysis of compound 4 yielded precursor 5, and subsequent reaction of compound 5 with propyl amine in the presence of EDC, HOBt, and DIPEA in DMF produced compound Be01 in 72% yield.
[0105] R f = 0.21 (7:3 ethyl acetate: methanol).
[0106] 1 H NMR (500 MHz, CD3OD) δ 7.81 (dd, J = 6.3 Hz, 1.5 Hz, 2H), 7.41 (d, J = 5.5 Hz, 2H), 6.99 (s, 1H), 6.35 (s, 1H), 4.72 (s, 2H), 3.33 (t, J= 7.5 Hz, 2H), 3.16-3.13 (m, 1H), 2.96 (s, 3H), 1.66-1.61 (m, 2H), 1.12 (d, J = 7.5 Hz, 6H), 0.97 (t, J = 7.5 Hz, 3H).
[0107] 13 C NMR (125 MHz, CD3OD) δ 173.9, 169.9, 158.5, 154.6, 142.2, 134.9, 128.6, 128.6, 127.9, 126.9, 114.6, 103.3, 42.8, 24.5, 23. 7,23. 1,11.8.
[0108] ESIMS ( m / e ) 371.19 [M+1] + .
[0109] Purity: 95.5% by HPLC
[0111] 4. Experimental Animal Information
[0112] The animal study was conducted with the approval of the Sunchon National University Animal Experimentation Research Committee (SCNU IACUC-2023-24).
[0113] C57BL / 6 mice (male, 8–12 weeks old, NCrlOri) and BALB / c mice (male, 6–7 weeks old, AnNCrlOri) were purchased from Orient-bio (Seongnam, Korea). The animals were confined in polycarbonate cages in a controlled environment (22 ± 2℃, humidity 50 ± 5%) and fed standard animal feed with water.
[0115] 5. Compound Screening Analysis
[0116] A total of 137 compounds were diluted in 1 mM dimethyl sulfoxide (DMSO) in 96-well plates. These plates were sealed with Parafilm and stored as mother plates at 4°C. Cells were treated with each compound at a concentration of 1 μM. Cells were cultured in cell culture medium (10% FBS, 1% sodium pyruvate, 1% anti-anti, 0.1% 2-mercaptoethanol, 25 mM HEPES, RPMI-1640) at a concentration of 5×10⁶ 5 Cells were inoculated into 96-well plates at a concentration of cells / well and cultured for 24 hours (37°C, 5% CO2). After culture, the expression of surface molecules on the cells was evaluated using flow cytometry. In addition, to confirm the anti-inflammatory effect, 1 μg / mL of lipopolysaccharide (LPS, Sigma-Aldrich, MO, USA) was added along with 1 μM of the compound.
[0118] 6. Toxicity Analysis
[0119] Splenocytes (5×10⁶ 5 cells / well) and peritoneal macrophages (1×10⁶ 5 Cells (1 / well) were inoculated into a 96-well plate, treated simultaneously with LPS (1 μg / mL) and compound (1 μM), and cultured for 24 hours (37°C, 5% CO2). After culture, half of the medium (100 μL) in each well was removed and CCK-8 reagent (10 μL, Cell counting kit-8, Dojindo, Kumamoto, Japan) was added. After 2 hours of culture (37°C, 5% CO2), optical density (OD) at 450 nm was evaluated using a microplate reader (Versa max, Molecular Devices, CA, USA).
[0121] 7. Flow cytometry
[0122] 5×10 cells 5Cells were suspended in a 5 mL tube containing FACS buffer (1% FBS in PBS) at a concentration of 100 μL / cells. To block Fc receptors, anti-mouse CD16 / 32 antibody (2.4G2, BD biosciences, NJ, USA) was added and incubated at 4°C for 30 minutes. Next, fluorescent conjugated antibodies [(FITC-CD11c (HL-1, BD biosciences, NJ, USA), FITC-CD11b (M1 / 70, Biolegend, CA, USA), PE-CD86 (GL-1, BD), PE-CD86 (16-10A1, BD), PE-CD40 (3 / 23, BD), PE-H-2Kb (AF6-88.5, BD biosciences, NJ, USA), PE-IA[b] (AF6-120.1, BD), PE-Gr-1 (RB6-8C5, Biolegend, CA, USA), APC-CD45 (30-F11, Biolegend, CA, USA), APC-Cy7-F4 / 80 (QA17A29, Biolegend, CA, USA)] were treated and incubated at 4°C for 30 minutes. Then, FACSCanto™ (BD biosciences, Cells were measured using (NJ, USA) and analyzed with Flow Jo software ver 10.8.1 (TreeStar, OR, USA).
[0124] 8. Enzyme-linked immunosorbent assay (ELISA)
[0125] ELISA was performed on the supernatant to evaluate the secretion levels of various cytokines (IL-6, TNF-α, IL-12 (p70), IL-1β) in cultured cells.
[0127] 9. Analysis of bone marrow-derived dendritic cells (BMDCs)
[0128] Bone marrow was collected from the tibia and femur of 6–8 week old male mice. RBCs were removed by treating cells with RBC lysis buffer. Cells were placed in cell culture dishes (2×10⁶) with GM-CSF (20 ng / mL, R&D systems) and IL-4 (1,000 U / mL, R&D systems, MN, USA). 6 Cells were inoculated into 20 mL of medium and cultured at 37°C at 5% CO2 for 6 days. Half of the medium was centrifuged to retain non-adherent cells, and fresh medium containing GM-CSF (20 ng / mL) and IL-4 (1,000 U / mL) was added to the cells. The medium was replaced every 2 days, and immature BMDCs were harvested after 6 days.
[0130] 10. Spleen CD11c + magnetic-activated cell sorting (MACS) of dendritic cells (sDC)
[0131] CD11c + CD11c from mouse splenocytes using the MicroBeads Ultrapure MACS kit (Miltenyi Biotec, Bergisch Gladbach, Germany) + The DC was disconnected. The experiment was performed according to the manufacturer's instructions.
[0133] 11. Proliferation Analysis of Ovalbumin (OVA)-Specific Th1 Cells and BMDC Co-cultures
[0134] To prepare the cells for the stationary phase, OVA-specific Th1 cells (HS-1) were cultured in 24-well plates for 18 days starting from the day of stimulation by mouse splenocytes treated with mitomycin C (Sigma-Aldrich, MO, USA). OVA (Sigma-Aldrich, MO, USA) and the compound were treated to immature BMDCs at 37°C and 5% CO2 for 18 hours. Subsequently, HS-1 (5×10⁶ 4 cells / well) BMDC (3×10 4The cells were co-cultured for 48 hours under the same conditions as cells / well. Then, cell viability was evaluated using a 5-bromo-2-uridine (5-bromo-2-uridine, BrdU) labeling kit (Sigma-Aldrich, MO, USA).
[0136] 12. Isolation of mouse peritoneal macrophages
[0137] After sacrificing C57BL / 6 mice (male, 6–8 weeks old) by CO2 inhalation, 10 mL of cold PBS was injected into the peritoneal cavity using a 10 mL syringe. Cells were harvested and counted to a value of 1 × 10⁶ 5 The cells were plated at a density of cells / well. Then, the plates were placed in an incubator at 37°C and 5% CO2 for 1 hour. After 1 hour, all wells were washed and non-adherent cells were removed, and the plates were incubated overnight under the same conditions.
[0139] 13. Nitric Oxide (NO) Analysis
[0140] Peritoneal macrophages (1×10⁶ 5 Cells (200 μL per well) were seeded into a 96-well plate. Then, the cells were simultaneously treated with LPS (1 μg / mL) and compound (1 μM) and cultured for 24 hours at 37°C in 5% CO2. After culture, 100 μL of the supernatant was collected from each well, and 100 μL of a 1:1 mixture of Griess reagents A and B was added to each supernatant. Subsequently, the mixture was incubated at room temperature for 10 minutes. Afterward, the absorbance at a wavelength of 550 nm was measured using a microplate reader (Versa max, Molecular Devices, CA, USA).
[0142] 14. Mouse OVA-Specific Delayed-Type Hypersensitivity (DTH) Model
[0143] BALB / c male mice (6 weeks old, n=15) were used in an OVA-specific DTH model and divided into three groups: control, OVA, and OVA + Be01. The OVA + Be01 group was sensitized by subcutaneously injecting 100 μL of OVA (100 μg / mL) emulsified with complete Freund's adjuvant (CFA, Sigma-Aldrich, MO, USA) into the base of the tail. After 6 days, 10 μL of heat-coagulated OVA (100 μg / 10 μL) was administered into the right auricle, and after 1 hour, the auricle thickness was measured using a dial thickness gauge (7301, Mitutoyo).
[0144] Delayed hypersensitivity was induced by heat agglutinating OVA in a water bath at 80°C for 1 hour with occasional cavitation. Be01 (100 μM, 100 μL) was injected daily into the mouse tail vein until the heat agglutinated OVA attack. The control group was treated only with PBS, whereas the positive control group was sensitized with OVA but received PBS into the auricle instead of heat agglutinated OVA. After a 24-hour test, auricle thickness was measured and the rate of thickness increase was evaluated (change in ear thickness 24 hours after OVA test). To confirm antigen-specific adaptive immune responses, mouse splenocytes were seeded into 24-well plates, treated with OVA (100 μg / mL), and cultured at 37°C at 5% CO2 for 24 hours.
[0146] 15. Mouse Acute Lung Injury (ALI) Model
[0147] Male C57BL / 6 mice (6 weeks old, n=9) were anesthetized by isoprene inhalation, and acute lung injury was induced by injecting LPS (5 mg / kg, 50 μL) into the mice's trachea. Immediately after tracheal infusion, Be01 (1 mM / 100 μL) was injected into the mice's tail vein. After 24 hours, bronchoalveolar lavage fluid (BALF) was collected from the mice four times, each mixed with 0.5 mL of PBS (37°C, containing 0.5% FBS and 2 mM EDTA). After centrifugation, the obtained cells were analyzed for neutrophils using flow cytometry, and cytokines in the supernatant were analyzed using ELISA.
[0149] 16. Histological evaluation
[0150] The harvested left lung and left ear were washed with PBS to remove blood and frozen at the optimal cutting temperature (OCT, Surgipath FSC 22, Leica, Wetzlar, Germany). Cryogenic tissue sections (lung: 14 μm, ear: 5 μm) were prepared using a cryo-microtome (Amos Scientific, Melbourne, Australia). The sections were washed with PBS to remove OCT residues. Subsequently, the tissues were stained using an H&E staining kit (hematoxylin and eosin, Abcam, Waltham, MA, USA) according to the manufacturer's instructions. Images were acquired using an EVOS M7000 microscope (lung: ×4, ear: ×20 air objectives). The captured images were analyzed using Image J and Celleste image analysis software ver. 5.0 (Thermo, Carthage, MO, USA).
[0152] 17. Statistical Analysis
[0153] Statistical analysis was performed using one-way analysis of variance (ANOVA), either using Student's t-test for comparison between two groups or Tukey's test for comparison between two or more groups. Statistical calculations were performed using SPSS ver. 27 (SPSS, IL, USA). A significance level of P < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). All values are expressed as mean ± standard deviation (SD).
[0155] <Experimental Results>
[0156] 1. Discovery of anti-inflammatory compounds through inhibition of CD86 expression
[0157] To develop anti-inflammatory compounds, a library of 137 Hsp90 inhibitors was tested. Referring to Figure 1, first, among the 137 compounds, CD (CD11 + Five compounds (Bd04, Bf01, Bc03, Be01, Bd03) exhibiting 20% inhibitory activity on CD86 expression were selected (Fig. 1a).
[0158] In addition, to mimic actual inflammation, the inhibitory effects of five candidates on the expression of the CD86 molecule were investigated when the state of splenocytes was stimulated with lipopolysaccharide (LPS). Upon LPS stimulation, CD86 expression in DCs increased 2.4-fold compared to the control group, whereas Be01 and Bf01 showed significant inhibitory activity on CD86 expression in response to LPS stimulation, increasing 1.6-fold and 1.9-fold, respectively (Fig. 1b).
[0159] Next, the expression levels of markers involved in T cell-associated signaling surface molecules, including CD80, MHC I, and MHC II, were investigated. Be01 inhibited the expression of all surface molecules, whereas Bf01 exhibited inhibitory activity only on MHC I and MHC II molecules (Fig. 1c).
[0160] In addition, cell viability was evaluated to determine whether the inhibitory effect of the two compounds was cytotoxic. Be01 did not exhibit cytotoxicity at any concentration, but Bf01 exhibited 44% cytotoxicity at a concentration of 1 μM (Fig. 1d).
[0161] Therefore, Be01 was selected as the final hit compound due to its non-toxic inhibitory effect on dendritic cell activation.
[0163] 2. Confirmation of the function of bone marrow-derived dendritic cells (BMDCs) and inhibition of antigen-specific immune responses by Be01
[0164] DCs express surface molecules and secrete cytokines to induce immune responses, including T cell activation and inflammation enhancement. Bone marrow-derived dendritic cells (BMDCs) were used to confirm the inhibitory effects of the Be01 compound on various factors.
[0165] Referring to Figure 2, antigen-presenting molecules such as CD40, CD80, CD86, MHC I, and MHC II for T cells were overexpressed upon LPS stimulation on the surface of DCs, but their expression was significantly reduced by Be01 treatment (Figure 2a). Interestingly, MHC I and MHC II were restored to levels similar to the untreated control group. Additionally, pro-inflammatory cytokines including IL-6, TNF-α, IL-12 (p70), and IL-1β were significantly reduced upon Be01 treatment (Figure 2b).
[0166] Meanwhile, the spleen is composed of various immune cells. To investigate the direct effects of Be01 on DCs, DCs were isolated from the spleen (sDC, purity >90%). sDCs showed observations similar to those of BMDCs. Be01 exerted a direct effect on DCs by significantly inhibiting the expression levels of LPS-induced signaling molecules, and also showed a significant reduction in the secretion levels of IL-6 and TNF-α exceeding 80%.
[0167] To verify the inhibitory effect of Be01 on DC function, the activation of antigen-specific T cells by Be01-treated DCs was evaluated. Referring to Figure 2c, co-culture with OVA-pulsed BMDCs increased the proliferation of OVA-specific Th1 cells and significantly elevated IFN-γ levels. In contrast, in Be01-treated BMDCs, the proliferation of OVA-specific Th1 cells decreased to a level similar to that of the unstimulated group, and the secretion of IFN-γ decreased by 60% (Figure 2d).
[0168] In summary, Be01 was confirmed to effectively regulate antigen-specific T cell responses in DCs through the inhibition of surface molecule expression and pro-inflammatory cytokine secretion.
[0170] 3. Confirmation of Anti-inflammatory Effects of Be01 on LPS-Stimulated Peritoneal Macrophages
[0171] As antigen-presenting cells, macrophages induce an inflammatory response by expressing surface molecules and secreting cytokines. To perform further anti-inflammatory analysis, peritoneal macrophages were isolated and stimulated with LPS (1 μg / mL), after which the effect of Be01 was evaluated (Fig. 3a).
[0172] Referring to Fig. 3, the non-cytotoxicity of Be01 was confirmed by peritoneal macrophages (Fig. 3b). Additionally, NO production decreased in a concentration-dependent manner during LPS (1 μg / mL) stimulation (25, 64, and 100%) (Fig. 3c). CD80 and CD86, co-stimulatory molecules for antigen presentation overexpressed on the surface of macrophages upon LPS stimulation, decreased by 22% and 30%, respectively, upon treatment with Be01 (Fig. 3d). Furthermore, the secretion of IL-6 and TNF decreased by 84% and 82%, respectively, while IL-1β was not detected, similar to the control group (Fig. 3e).
[0173] In summary, Be01 was found to effectively regulate the initial inflammatory response by inhibiting the expression of surface molecules and the secretion of pro-inflammatory cytokines in both DCs and macrophages.
[0175] 4. Confirmation of the therapeutic effect of Be01 on delayed-type hypersensitivity (DTH) and acute lung injury (ALI) models
[0176] Previous results confirmed that Be01 effectively regulates the antigen-specific response of Th1 cells by reducing CD86 and MHC II molecules in APCs. For further analysis, Be01 in vivo ( in vivo A DTH model was used to determine whether inflammation could be controlled (Fig. 4a). Through H&E-stained left auricular tissue, it was confirmed that ear edema and infiltrating immune cells were reduced in the Be01-treated group (Fig. 4b).
[0177] To confirm the inflammatory response, ear thickness was measured. Compared to the DTH-induced group, ear thickness in the Be01-treated group decreased significantly by 73% (Fig. 4c).
[0178] In addition, to confirm systemic immune balance, splenocytes isolated from each group of mice were cultured, and levels of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β were measured. Compared to the positive control group, IL-6 was reduced by 49%, TNF-α by 17%, and IL-1β by 49% in the splenocytes of the Be01-treated group (Fig. 4d).
[0179] Subsequently, we evaluated whether Be01 induced acute lung injury (ALI) and controlled early inflammation in an animal model (Fig. 4e). When evaluating immune cell infiltration into the lungs, it was found that immune cell density decreased with Be01 treatment compared to the LPS-treated group (Fig. 4f).
[0180] In addition, BALF was analyzed to investigate whether Be01 regulates neutrophil infiltration and cytokine secretion. As a result, neutrophils (CD45 + / CD11b + / Gr-1 + ) was reduced (Fig. 4g). In addition, in an ALI model, inflammatory cytokines IL-6, TNF-α, IL-12 (p70), and IL-1β were reduced by Be01 treatment (Fig. 4h).
[0182] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. That is, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of inflammatory or immune diseases, comprising as an active ingredient a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof, wherein the inflammatory or immune disease is acute lung injury (ALI) or delayed-type hypersensitivity (DTH) caused by a cytokine storm: <Chemical Formula 1> Claim 2 A pharmaceutical composition according to claim 1, wherein the compound or its salt inhibits the expression of a T cell-associated marker selected from the group consisting of CD86, CD80, MHC I, and MHC II on the surface of dendritic cells or macrophages. Claim 3 A pharmaceutical composition according to claim 1, wherein the compound or its salt inhibits the secretion of a pro-inflammatory cytokine selected from the group consisting of IL-6, TNF-α, IL-12 (p70), IL-1β, and IFN-γ. Claim 4 A pharmaceutical composition according to claim 1, characterized in that the compound or salt thereof is a heat shock protein 90 (Hsp90) inhibitor. Claim 5 A pharmaceutical composition according to claim 1, wherein the compound or salt thereof is characterized by inhibiting a cytokine storm. Claim 6 delete Claim 7 A health functional food composition for the prevention or improvement of inflammatory or immune diseases, comprising as an active ingredient a compound represented by the following chemical formula 1 or a food-grade acceptable salt thereof, wherein the inflammatory or immune disease is acute lung injury (ALI) or delayed-type hypersensitivity (DTH) caused by a cytokine storm: <Chemical Formula 1> Claim 8 delete Claim 9 A method for inhibiting a cytokine storm in acute lung injury (ALI) or delayed-type hypersensitivity (DTH), comprising the step of treating a mammal other than a human with a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof: <Chemical Formula 1> Claim 10 delete
Citation Information
Patent Citations
New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp90
KR1020090080948A
New benzamide compound or pharmaceutically acceptable salt thereof having inhibitory activity on Hsp90 and medical use thereof
KR102010274B1
NOVEL COMPOUND HAVING Hsp90 AND HDAC6 INHIBITORY ACTIVITY AND USE THEREOF
KR1020230105807A
Amide resorcinol compounds
WO2006117669A1
